Only 29% of People With Diabetes Report That Their Doctors ask Them for Input for Their own Treatment Plans

PR55228

MELBOURNE, Australia, Dec 5, 2013 /PRN=KYODO  JBN/

    Results from the global Diabetes Attitudes, Wishes and Needs 2 study

(DAWN2(TM)) presented today at a symposium during the World Diabetes Congress

of the International Diabetes Federation (IDF), show that only 29% of people

with diabetes report that their healthcare team ask for their input when making

their treatment plans. Furthermore, only 33% said they were encouraged by their

healthcare professional to ask questions in the consultation.

These results are surprising, given the importance of active involvement of

people with diabetes in their own treatment and care. In fact, 84% of

healthcare professionals who took part in the study said it would be helpful if

their patients prepared questions in advance of the consultation[1].

    To view the Multimedia News Release, please click:

http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment

    "People with diabetes who feel supported and capable of self-managing their

condition are more likely to have a successful treatment outcome and therefore

have the opportunity to live a better life with diabetes,"explained Ingrid

Willaing, head of Education Research at the Steno Diabetes Center and lead

national investigator for DAWN2(TM) in Denmark, during her symposium

presentation. "The DAWN2(TM) study highlights that far too few people with

diabetes are supported to take an active role".

    To help break down communication barriers and misconceptions about diabetes

treatments and thereby improve effective self-management of type 2 diabetes,a

theatre play called "Getting Straight to the Point" was held at the Congress on

4 December. Here, a panel of leading diabetes experts called for both

healthcare professionals and people with type 2 diabetes to create

opportunities for open dialogue, shared decision-making and active engagement

for better physical and emotional outcomes.

    A series ofother global DAWN2(TM)results were announced during the Congress

highlighting the insufficiencies relating to quality of life with diabetes,

support for families, access to diabetes education and psychosocial support,

positive awareness of diabetes in society and attention to the special needs of

vulnerable populations with diabetes.

    "The DAWN2(TM) study calls for united efforts across stakeholders and

nations to advance a person-centred approach to improve prevention, care,

education and support for people with diabetes and their families," says Sir

Michael Hirst, president of the International Diabetes Federation.

    DAWN2(TM) represents the voices of more than 15,000 people with diabetes,

their family members and healthcare professionals in 17 countries across 4

continents.

    About DAWN2(TM)

    DAWN2(TM) is a global Novo Nordisk initiative conducted in collaboration

with the IDF, the International Alliance of Patients' Organizations (IAPO), the

Steno Diabetes Center and a range of other national, regional and global

partners. The DAWN2(TM) results highlight opportunities for improving diabetes

care, education and community support by putting people with diabetes and their

families centre stage. The DAWN2(TM) study will be used internationally and

nationally to facilitate dialogue among patient organisations, healthcare

professionals and other key stakeholders to develop action plans for

improvement of the lives of people with diabetes. Further information is

available at http://www.dawnstudy.com.

    About Novo Nordisk

    Headquartered in Denmark, Novo Nordisk is a global healthcare company with

90 years of innovation and leadership in diabetes care. The company also has

leading positions within haemophilia care, growth hormone therapy and hormone

replacement therapy. Novo Nordisk employs approximately 37,000 employees in 75

countries, and markets its products in more than 180 countries. For more

information, visit novonordisk.com.

    Further information

    Media:

    Daniel Vamosi Martinussen

    +45-3079-1879

    dvmm@novonordisk.com

    Ken Inchausti (US)

    +1-609-514-8316

    kiau@novonordisk.com

    Investors:

    Kasper Roseeuw Poulsen

    +45-4442-4303

    krop@novonordisk.com

    Frank Daniel Mersebach

    +45-4442-0604

    fdni@novonordisk.com

    Daniel Bohsen

    +45-3079-6376

    dabo@novonordisk.com

    Lars Borup Jacobsen

    +45-3075-3479

    lbpj@novonordisk.com

    Jannick Lindegaard (US)

    +1-609-786-4575

    jlis@novonordisk.com

    References

    1. I. Willaing, DAWN2(TM) Study Results: Involvement and Education. Oral

Lecture, DAWN2(TM) Symposium, 5 December 2013, World Diabetes Congress of the

International Diabetes Federation (IDF).

    SOURCE: Novo Nordisk, DAWN2TM, International Diabetes Federation, Steno

Diabetes Center